Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2024-11-07 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
113年第3季綜合損益表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated comprehensive income statement with detailed financial data for the third quarter of the 113th year (likely referring to a fiscal year in the Taiwanese calendar) and comparative figures from the previous year. It includes revenue, costs, expenses, profit, and earnings per share data. The presence of actual financial statements and substantive financial data for a period shorter than a full fiscal year (quarterly data) indicates this is a quarterly or interim financial report. The document length is 3140 characters, which is relatively short but contains detailed financial tables, not just an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-11-07 Chinese
113年第3季資產負債表
Interim / Quarterly Report Classification · 95% confidence The document contains a consolidated balance sheet with detailed financial data for multiple periods, including specific asset, liability, and equity line items with amounts and percentages. The presence of actual financial statements and substantive financial data for a quarterly period (third quarter of year 113 in the Taiwanese calendar, corresponding to 2024 Q3) indicates this is a financial report for a period shorter than a full fiscal year. The document length is 3920 characters, which is relatively short but contains actual financial data rather than just an announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q3 2024
2024-11-07 Chinese
113年10月內部人持股異動(事後)
Director's Dealing Classification · 100% confidence The document contains detailed tables listing shareholdings of company insiders, including directors, managers, and their related parties. It shows changes in share ownership, types of shares held, and other related data. There is no indication of financial statements, earnings data, or meeting materials. The content is focused on insider share transactions and holdings. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades). The document length is sufficient and the content is substantive, not just an announcement or certification. Therefore, the appropriate classification is DIRS.
2024-11-05 Chinese
113年10月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings and pledged shares by company insiders, including directors and senior management. It lists current holdings, pledged shares, and related percentages. The content focuses on insider shareholdings and pledges rather than financial results, management changes, or meeting materials. This matches the description of a Director's Dealing report, which covers personal share transactions or holdings by company directors and executives. The document is relatively short (2484 characters) and does not mention any report publication or certification. Therefore, the best fitting category is Director's Dealing (DIRS).
2024-11-05 Chinese
公告本公司113年第3季合併財務報告預計提報董事會召開 日期
Report Publication Announcement Classification · 95% confidence The document is a short announcement (540 characters) from a company (1786 科妍) stating the planned submission of the Q3 consolidated financial report to the board and the date of the board meeting. It does not contain the actual financial report or detailed financial data but only informs about the upcoming board meeting and report submission. According to the 'Menu vs Meal' rule, such a brief notice about a report to be presented is classified as a Report Publication Announcement (RPA), not the report itself (IR).
2024-10-30 Chinese
113年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a company named 科妍, providing information about the status of fund loans and endorsements/guarantees for the current and previous month, with amounts all zero. It is a short, factual update without detailed financial statements or analysis. There is no indication of a full report, audit, or management discussion. The content fits the profile of a regulatory announcement or compliance disclosure rather than a full financial report or other specific filing types. Given the short length (601 characters) and the nature of the content, it is best classified as a Regulatory Filing (RNS).
2024-10-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.